Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fsd Pharma Inc Cl B (NQ: HUGE )

0.0899 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0899
Bid (Size) 0.0916 (134)
Ask (Size) 0.0934 (80)
Prev. Close 0.0899
Today's Range 0.0899 - 0.0899
52wk Range 0.0720 - 1.500
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update
Via ACCESSWIRE
HUGE Stock Earnings: FSD Pharma Misses EPS for Q2 2024
HUGE stock results show that FSD Pharma missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
-90.01%
-90.01%
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
-73.56%
-73.56%
1 Year
-93.34%
-93.34%

More News

Read More
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Why Rumble Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why FSD Pharma Stock Is Seeing Huge Gains
Via Benzinga
FSD Pharma Rebrands As Quantum BioPharma: Major Share Consolidation Announced
Via Benzinga
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Shareholders Approve Plans for Share Consolidation, Name Change
Via Investor Brand Network
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
Via Benzinga
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Reports on Status of New Product, Investment in Celly Nutrition Corp.
Via Investor Brand Network
US Stocks Edge Lower; EchoStar Shares Tumble After Q2 Results
Via Benzinga
FSD Pharma Is Up 216% Today. What Is Going On With HUGE Stock?
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
Via Benzinga
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp. Who Secures Additional Financing to Launch unbuzzd(TM) Stick Packs this Month - Created by a World-Class Pharmaceutical Research & Development Team
Via ACCESSWIRE
Why Carvana Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
InvestorNewsBreaks – FSD Pharma Inc.’s (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) Revolutionary Rapid Detoxification Drink Spotlighted in 24/7 Market News Report
Via Investor Brand Network
BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Holds Annual General and Special Meeting of Shareholders, Reports on Voting Results
Via Investor Brand Network
BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Amends Original Material Change Report, Files Amended and Restated MCR
Via Investor Brand Network
BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Retains Digital Marketing Platform to Increase Market Awareness
Via Investor Brand Network
FSD Pharma provides Corporate Update
Via ACCESSWIRE
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Awarded Final Judgment, Confirmation of $3M-Plus Arbitration Award
Via Investor Brand Network
FSD Pharma, Inc. Wins Final Judgment to Confirm Arbitration Award of $3,059,998 Plus Interest Entered Against Dr. Raza Bokhari, Currently Serving as Chairman and CEO of Medicus Pharma Ltd.
Via ACCESSWIRE
BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Notes ‘Important Step’ as Phase 1 Lucid-21-302 Trial Receives HREC Approval
Via Investor Brand Network
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Notes ‘Important Step’ as Phase 1 Lucid-21-302 Trial Receives HREC Approval
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.